Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Bali

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Dr Liga Participants: Prof.Spyridonidis, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Excellent review on HMA, their clinical use  and mechnisms on resistance. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Comprehensive excellent review https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370557/ Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Journal of Clinical Oncology. 2021 Apr 27; National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. Bronwen E Shaw, Antonio Martin Jimenez-Jimenez, Linda J Burns, Brent R Logan, Farhad Khimani, Brian C Shaffer, Nirav N Shah, Alisha Mussetter,...

Cancer. 2021 Mar 18; Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Hagop M Kantarjian, Tapan M Kadia, Courtney D DiNardo, Mary Alma Welch, Farhad Ravandi PMID: 33734442 Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Excellent case based report on npm1 Mut Aml  Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Comprehensive review for AML treatment. New directions applied in MD Anderson CC Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

New guidelines for treatment of MM (EHA/ESMO) Presenter S. Kastritis Participation Spyridonidis, Liga, Tsokanas Diagnostic obligatory are still Free light chain serum, 24-Urin, cytogenetics (Del17p, t(4,14), WBLD-CT and if  negative Whole body MRI. Asymptomatic MM (use 20/2/20 score), if high (2 of 3) risk score these pats...

https://www.ebmt.org/sites/default/files/2021-02/EBMT%20COVID-19%20guidelines%20v.%2015.02%202021-02-18.pdf Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

Ebmt proposes to vaccinate after day 100 https://www.ecdc.europa.eu/en/publications-data/coronavirus-disease-2019-covid-19-and-supply-substances-human-origin Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka

An important paper published in Blood showed that prophylaxis is not  always wihtout harm. Pts under letermovir prophylaxis may be at risk for  late CMV infection after HCT because of delay CMV-specific cellular  reconstitution (which is due to the letermovir induced decreased CMV  antigen exposure). JOURNAL ARTICLE Cytomegalovirus-specific T-cell Reconstitution...